Dataset Information

No genetic association between A118G polymorphism of μ-opioid receptor gene and schizophrenia and bipolar disorders.

ABSTRACT:

Background

Schizophrenia (SZ) and bipolar disorder (BD) are chronic and multifactorial psychiatric disorders that might be affected by different genes in combination with environmental factors. There is evidence of association between polymorphisms of μ-opioid receptor gene (OPRM1) with these disorders.

Objectives

The aim of this study was to investigate the genetic association between OPRM1 A118G SNP in SZ and BD patients in comparison with healthy controls (HCs).

Materials and methods

One single-nucleotide polymorphism in OPRM1 was genotyped using TaqMan real-time PCR assay in 203 SZ and BD patients and 389 HCs.

Results

There was no statistically significant difference in genotypic and allelic frequencies of OPRM1 A118G SNP between HCs and SZ/BD patients.

Conclusions

To find the underlying genetic factors associated with these complex disorders, further studies need to be conducted using larger sample size, different genetic populations, and different gene variations.

SUBMITTER: Yazdani S

PROVIDER: S-EPMC5806329 | biostudies-literature | 2017 Oct-Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

No genetic association between A118G polymorphism of μ-opioid receptor gene and schizophrenia and bipolar disorders.

Yazdani Shaghayegh S Salimi Vahid V Eshraghian Mohammad Reza MR Shayestehpour Mohammad M Pourtalebi-Firoozabadi Alireza A Romani Bizhan B Shadab Azadeh A Aghasadeghi Mohammad Reza MR Yavarian Jila J

Indian journal of psychiatry 20171001 4

<h4>Background</h4>Schizophrenia (SZ) and bipolar disorder (BD) are chronic and multifactorial psychiatric disorders that might be affected by different genes in combination with environmental factors. There is evidence of association between polymorphisms of μ-opioid receptor gene (OPRM1) with these disorders.<h4>Objectives</h4>The aim of this study was to investigate the genetic association between OPRM1 A118G SNP in SZ and BD patients in comparison with healthy controls (HCs).<h4>Materials an ...[more]

PMID: 29497192

Similar Datasets

Project description:Mu-opioid receptors (MOPRs) are critically involved in the modulation of pain and analgesia, and represent a candidate mechanism for the development of biomarkers of pain conditions and their responses to treatment. To further understand the human implications of genetic variation within the opioid system in pain and opioid-mediated placebo responses, we investigated the association between the functional single-nucleotide polymorphism (SNP) in the μ-opioid receptor gene (OPRM1), A118G, and psychophysical responses, personality traits, and neurotransmitter systems (dopamine (DA), opioid) related to pain and placebo analgesia. OPRM1 G carriers, compared with AA homozygotes, showed an overall reduction of baseline μ-opioid receptor availability in regions implicated in pain and affective regulation. In response to a sustained painful stimulus, we found no effect of A118G on pain-induced endogenous opioid release. Instead, AA homozygotes showed a blunted DA response in the nucleus accumbens (NAc) in response to the pain challenge. After placebo administration, G carriers showed more pronounced mood disturbances and lower placebo-induced μ-opioid system activation in the anterior insula (aINS), the amygdala (AMY), the NAc, the thalamus (THA), and the brainstem, as well as lower levels of DA D2/3 activation in the NAc. At a trait level, G carriers reported higher NEO-Neuroticism scores; a personality trait previously associated with increased pain and lower placebo responses, which were negatively correlated with baseline μ-opioid receptor availability in the aINS and subgenual anterior cingulate cortex (sgACC). Our results demonstrate that the A118G OPRM1 polymorphism contributes to interindividual variations in the function of neurotransmitters responsive to pain (endogenous opioid and dopamine), as well as their regulation through cognitive-emotional influences in the context of therapeutic expectations, the so-called placebo effect. These effects are relevant to human vulnerability to disease processes where these neurotransmitters have a role, such as persistent pain, mood, and substance use disorders, and responses to their treatments.

Dataset Information

No genetic association between A118G polymorphism of μ-opioid receptor gene and schizophrenia and bipolar disorders.

Background

Objectives

Materials and methods

Results

Conclusions

Publications

No genetic association between A118G polymorphism of μ-opioid receptor gene and schizophrenia and bipolar disorders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets